In preclinical models of MB, JQ1 and OTX015, bromodomain and extraterminal (BET) inhibitors suppress oncogenic pathways in MBs driven by MYC (173, 174), GLI1 and GLI2 (175) and MYCN (176) via functional inhibition of BRD4. The gene discussed is MYCN; the disease is Mobius syndrome.